back to cluster viewer
cluster path 101111101010
110 words, 21,250 tokens
freq alpha suffix
Words in frequency order
1 | average | 20,974
|
2 | behalf | 76
|
3 | kiel | 11
|
4 | ed99 | 8
|
5 | insulin-modified | 8
|
6 | upper-limit | 7
|
7 | 18-point | 6
|
8 | apex-to-base | 6
|
9 | ultralong | 6
|
10 | year-2003 | 5
|
11 | f-statistic | 4
|
12 | lfhfd | 4
|
13 | non-extreme | 4
|
14 | 3000-mg | 3
|
15 | 4,333 | 3
|
16 | apex-base | 3
|
17 | eighteen-item | 3
|
18 | es-ed | 3
|
19 | ncdh | 3
|
20 | pet-ct. | 3
|
21 | source-based | 3
|
22 | 'matte | 2
|
23 | 14-18-year | 2
|
24 | 30-nm | 2
|
25 | 5364 | 2
|
26 | acupunc | 2
|
27 | anti-apoa-ii | 2
|
28 | aquacoat | 2
|
29 | cm10 | 2
|
30 | eoma | 2
|
31 | forward-scatter | 2
|
32 | increase/a | 2
|
33 | index-the | 2
|
34 | low-humidity | 2
|
35 | npi-sum-severity | 2
|
36 | patients'quality | 2
|
37 | pvc-based | 2
|
38 | ultra-high-efficiency | 2
|
39 | upper-end | 2
|
40 | 'isolation | 1
|
41 | 1,000-mg. | 1
|
42 | 111th | 1
|
43 | 13,432 | 1
|
44 | 2,000-mg. | 1
|
45 | 3'-hydroxylation | 1
|
46 | 300-mg/150-mg | 1
|
47 | 79,000 | 1
|
48 | 87th | 1
|
49 | 88-minute | 1
|
50 | 9.6mg | 1
|
51 | adulterantin | 1
|
52 | aetiology/duration | 1
|
53 | age-compatible | 1
|
54 | apbm | 1
|
55 | ascuson | 1
|
56 | bromination-evaporation | 1
|
57 | chimerization | 1
|
58 | cognistat | 1
|
59 | copd/breathing-related | 1
|
60 | cytospins | 1
|
61 | ene-cyclization | 1
|
62 | estimate=1.05 | 1
|
63 | estimate=1.15 | 1
|
64 | estimate=1.23 | 1
|
65 | etravirine/water | 1
|
66 | ex4-induced | 1
|
67 | functionality.42 | 1
|
68 | genprobe | 1
|
69 | hand/number | 1
|
70 | hcort-associated | 1
|
71 | healthcare-utilization | 1
|
72 | height-corrected | 1
|
73 | hit-false | 1
|
74 | hrm-enabled | 1
|
75 | individualized-tumour | 1
|
76 | intercentroid | 1
|
77 | ion-rich | 1
|
78 | ir-mph-administered | 1
|
79 | irremovable | 1
|
80 | leptin-to-high | 1
|
81 | median-dichotomised | 1
|
82 | metatheses | 1
|
83 | mis-disordered | 1
|
84 | misreadings | 1
|
85 | multi-gigatonne | 1
|
86 | nchs-based | 1
|
87 | non-extensional | 1
|
88 | online-monitored | 1
|
89 | opisthoglyphous | 1
|
90 | or=3.14 | 1
|
91 | patient-requested | 1
|
92 | pba-episode | 1
|
93 | pharmacokenetics | 1
|
94 | photo-phase | 1
|
95 | photofunctions | 1
|
96 | pre-dbs | 1
|
97 | read-back | 1
|
98 | relapset | 1
|
99 | retardation/regression | 1
|
100 | rs3740400 | 1
|
101 | site-rated | 1
|
102 | tietze-potter | 1
|
103 | tiltings | 1
|
104 | ublinded | 1
|
105 | vitosha | 1
|
106 | who-provided | 1
|
107 | within-year | 1
|
108 | κ=0.35 | 1
|
109 | ∼10-mmhg | 1
|
110 | ∼15-min | 1
|
Words in alphabetical order
1 | 'isolation | 1
|
2 | 'matte | 2
|
3 | 1,000-mg. | 1
|
4 | 111th | 1
|
5 | 13,432 | 1
|
6 | 14-18-year | 2
|
7 | 18-point | 6
|
8 | 2,000-mg. | 1
|
9 | 3'-hydroxylation | 1
|
10 | 30-nm | 2
|
11 | 300-mg/150-mg | 1
|
12 | 3000-mg | 3
|
13 | 4,333 | 3
|
14 | 5364 | 2
|
15 | 79,000 | 1
|
16 | 87th | 1
|
17 | 88-minute | 1
|
18 | 9.6mg | 1
|
19 | acupunc | 2
|
20 | adulterantin | 1
|
21 | aetiology/duration | 1
|
22 | age-compatible | 1
|
23 | anti-apoa-ii | 2
|
24 | apbm | 1
|
25 | apex-base | 3
|
26 | apex-to-base | 6
|
27 | aquacoat | 2
|
28 | ascuson | 1
|
29 | average | 20,974
|
30 | behalf | 76
|
31 | bromination-evaporation | 1
|
32 | chimerization | 1
|
33 | cm10 | 2
|
34 | cognistat | 1
|
35 | copd/breathing-related | 1
|
36 | cytospins | 1
|
37 | ed99 | 8
|
38 | eighteen-item | 3
|
39 | ene-cyclization | 1
|
40 | eoma | 2
|
41 | es-ed | 3
|
42 | estimate=1.05 | 1
|
43 | estimate=1.15 | 1
|
44 | estimate=1.23 | 1
|
45 | etravirine/water | 1
|
46 | ex4-induced | 1
|
47 | f-statistic | 4
|
48 | forward-scatter | 2
|
49 | functionality.42 | 1
|
50 | genprobe | 1
|
51 | hand/number | 1
|
52 | hcort-associated | 1
|
53 | healthcare-utilization | 1
|
54 | height-corrected | 1
|
55 | hit-false | 1
|
56 | hrm-enabled | 1
|
57 | increase/a | 2
|
58 | index-the | 2
|
59 | individualized-tumour | 1
|
60 | insulin-modified | 8
|
61 | intercentroid | 1
|
62 | ion-rich | 1
|
63 | ir-mph-administered | 1
|
64 | irremovable | 1
|
65 | kiel | 11
|
66 | leptin-to-high | 1
|
67 | lfhfd | 4
|
68 | low-humidity | 2
|
69 | median-dichotomised | 1
|
70 | metatheses | 1
|
71 | mis-disordered | 1
|
72 | misreadings | 1
|
73 | multi-gigatonne | 1
|
74 | ncdh | 3
|
75 | nchs-based | 1
|
76 | non-extensional | 1
|
77 | non-extreme | 4
|
78 | npi-sum-severity | 2
|
79 | online-monitored | 1
|
80 | opisthoglyphous | 1
|
81 | or=3.14 | 1
|
82 | patient-requested | 1
|
83 | patients'quality | 2
|
84 | pba-episode | 1
|
85 | pet-ct. | 3
|
86 | pharmacokenetics | 1
|
87 | photo-phase | 1
|
88 | photofunctions | 1
|
89 | pre-dbs | 1
|
90 | pvc-based | 2
|
91 | read-back | 1
|
92 | relapset | 1
|
93 | retardation/regression | 1
|
94 | rs3740400 | 1
|
95 | site-rated | 1
|
96 | source-based | 3
|
97 | tietze-potter | 1
|
98 | tiltings | 1
|
99 | ublinded | 1
|
100 | ultra-high-efficiency | 2
|
101 | ultralong | 6
|
102 | upper-end | 2
|
103 | upper-limit | 7
|
104 | vitosha | 1
|
105 | who-provided | 1
|
106 | within-year | 1
|
107 | year-2003 | 5
|
108 | κ=0.35 | 1
|
109 | ∼10-mmhg | 1
|
110 | ∼15-min | 1
|
Words in suffix order
1 | 1,000-mg. | 1
|
2 | 2,000-mg. | 1
|
3 | pet-ct. | 3
|
4 | 79,000 | 1
|
5 | rs3740400 | 1
|
6 | cm10 | 2
|
7 | 13,432 | 1
|
8 | functionality.42 | 1
|
9 | year-2003 | 5
|
10 | estimate=1.23 | 1
|
11 | 4,333 | 3
|
12 | or=3.14 | 1
|
13 | 5364 | 2
|
14 | estimate=1.05 | 1
|
15 | estimate=1.15 | 1
|
16 | κ=0.35 | 1
|
17 | ed99 | 8
|
18 | increase/a | 2
|
19 | vitosha | 1
|
20 | eoma | 2
|
21 | f-statistic | 4
|
22 | acupunc | 2
|
23 | es-ed | 3
|
24 | ex4-induced | 1
|
25 | who-provided | 1
|
26 | ublinded | 1
|
27 | insulin-modified | 8
|
28 | hrm-enabled | 1
|
29 | mis-disordered | 1
|
30 | ir-mph-administered | 1
|
31 | online-monitored | 1
|
32 | pvc-based | 2
|
33 | source-based | 3
|
34 | nchs-based | 1
|
35 | median-dichotomised | 1
|
36 | hcort-associated | 1
|
37 | copd/breathing-related | 1
|
38 | site-rated | 1
|
39 | height-corrected | 1
|
40 | patient-requested | 1
|
41 | lfhfd | 4
|
42 | intercentroid | 1
|
43 | upper-end | 2
|
44 | genprobe | 1
|
45 | pba-episode | 1
|
46 | average | 20,974
|
47 | index-the | 2
|
48 | irremovable | 1
|
49 | age-compatible | 1
|
50 | non-extreme | 4
|
51 | multi-gigatonne | 1
|
52 | apex-to-base | 6
|
53 | apex-base | 3
|
54 | photo-phase | 1
|
55 | hit-false | 1
|
56 | 'matte | 2
|
57 | 88-minute | 1
|
58 | behalf | 76
|
59 | ∼10-mmhg | 1
|
60 | 3000-mg | 3
|
61 | 300-mg/150-mg | 1
|
62 | 9.6mg | 1
|
63 | ultralong | 6
|
64 | ion-rich | 1
|
65 | ncdh | 3
|
66 | leptin-to-high | 1
|
67 | 111th | 1
|
68 | 87th | 1
|
69 | anti-apoa-ii | 2
|
70 | read-back | 1
|
71 | non-extensional | 1
|
72 | kiel | 11
|
73 | apbm | 1
|
74 | eighteen-item | 3
|
75 | 30-nm | 2
|
76 | ∼15-min | 1
|
77 | adulterantin | 1
|
78 | retardation/regression | 1
|
79 | 'isolation | 1
|
80 | 3'-hydroxylation | 1
|
81 | bromination-evaporation | 1
|
82 | aetiology/duration | 1
|
83 | ene-cyclization | 1
|
84 | healthcare-utilization | 1
|
85 | chimerization | 1
|
86 | ascuson | 1
|
87 | 14-18-year | 2
|
88 | within-year | 1
|
89 | hand/number | 1
|
90 | etravirine/water | 1
|
91 | forward-scatter | 2
|
92 | tietze-potter | 1
|
93 | individualized-tumour | 1
|
94 | pre-dbs | 1
|
95 | pharmacokenetics | 1
|
96 | metatheses | 1
|
97 | misreadings | 1
|
98 | tiltings | 1
|
99 | cytospins | 1
|
100 | photofunctions | 1
|
101 | opisthoglyphous | 1
|
102 | aquacoat | 2
|
103 | cognistat | 1
|
104 | relapset | 1
|
105 | upper-limit | 7
|
106 | 18-point | 6
|
107 | ultra-high-efficiency | 2
|
108 | low-humidity | 2
|
109 | patients'quality | 2
|
110 | npi-sum-severity | 2
|